Symbiotec Pharmalab

IPO Size: Rs.1,757 cr

• Fresh Issue of Rs. 150 cr (2% dilution) to repay Rs. 113 cr of Rs. 388 cr gross debt
• Offer for Sale (OFS) of Rs. 1,607 cr, 91% of OFS by two funds (59% combined stake to drop to 35% post IPO) and 9% by promoter (36% to shrink to 33%)

Price band: Rs. 938-988 per share

M cap: Rs. 6,348 cr (IPO is 28% of m cap)

IPO Date: Mon 24^th Aug to Thu 27^th Aug 2026, Listing Tue 1^st Sep 2026

Grey Market Premium (GMP): We are strongly against ‘grey market premium’ as it is an unofficial figure, against SEBI guidelines.

 

Research-driven Pharma Company

Symbiotec Pharmalab is a 31-year-old Indore-based vertically-integrated pharma and biotechnology company, being the only Indian and global manufacturer with presence across top ten corticosteroid and hormone APIs. It is a leader in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) with global volume market share of 38% and 24% respectively in FY26. With US FDA and EU-GMP approvals, 67% of Rs. 869 cr revenue was generated from exports in FY26.  

 

High Growth Visibility

Net fixed assets have increased 2.5x on 31.3.26 to Rs. 1,084 cr, from Rs. 396 cr a year ago. For FY26, it operated 2 API facilities with maximum chemical synthesis capacity of 585 MT and 300 KL fermentation capacity. On 31.3.26, it commissioned two additional facilities in Madhya Pradesh, more than doubling the fermentation capacity to 700 KL, and adding complex injectables capacity of 20 million vials per annum.

In addition to this, it is also expanding biologics fermenting capacity by 14 KL to cater to the increasing demand for GLP-1 and Insulin.

Leveraging capabilities across 3 verticals of organic chemistry, biotechnology and complex injectables, it started operating as a contract development and manufacturing organisation (CDMO) in FY25, which is another growth area.

Thus, Rs, 1,000 cr investment in capex over the past 4 fiscals since FY23, is yielding results. Moreover, a significant portion is yet to be reflect in financials, and is likely in FY27E, as it operates at fixed asset turn of 1.8-2.0x.

 

High Margin Business

Due to niche products and 3-4% of annual revenue invested in R&D, company clocks superlative margin – 64% gross, 27% EBITDA and 13% net. FY26 EBITDA stood at Rs. 237 cr, with PAT of Rs. 110 cr. On small equity of Rs.12.5 cr (face value Rs. 2 each), EPS for FY26 stood at Rs. 19.  

RoE shrunk to 11.2% in FY26, mainly due to capex already undertake, is likely to jump to 18% going forward. On net worth of Rs. 1,150 cr, net debt to equity ratio of 0.3:1 will shrink to 0.2:1 post IPO.  

 

Undemanding Pricing

FY26 PE of 56x make appear high, but M cap of Rs. 6,348 cr is attractive based on FY27E expected EPS of close to Rs. 35, implying a current year PE multiple of only 28x. This is undemanding for double-digit net margin, high-teen RoE, immediate growth trigger due to new capacity already commissioned.